Plan to Evaluate Early Endothelialization of a Polymer Free Sirolimus-eluting Coronary Stent System (VIVO ISARTM) Compared With Everolimus-eluting Durable Polymer Stent (XIENCE SkypointTM) in Patients Undergoing Percutaneous Coronary Intervention.

Inclusion Criteria: * Patients with age ≥ 18 years AND * Patients who have signed informed consent AND * Patients with coronary artery disease requiring percutaneous treatment with coronary stents due to de novo lesions in vessels with a diameter of reference from 2.25 mm to 4.0 mm AND * Patients with at least 2 angiographic lesions in 2 different major coronary arteries. Or in the main branch and in one of its subsidiaries branches , as long as those are not "downstream" of the lesion from the main branch Exclusion Criteria: * Express refusal of the patient to participate in the study * Patients with ST elevation Myocardial Infarction or Cardiogenic Shock * Patients with high thrombotic content * Pregnant or breastfeeding patients * Patients with complex PCI (Percutaneous Coronary Intervention )(defined as): * Left main PC * Chronic total PC occlusion * Bifurcation lesion requiring 2-stent technique . * Severe calcified lesion (need to use prior complex techniques of calcium modification such as intravascular lithotripsy, rotational/orbital atherectomy, laser. * Patients with malignant neoplasms or other comorbid conditions with life expectancy \<12 months * Patients with a target lesion in a bypass graft * Lesions due to restenosis * Patients with PCI in the target vessel in the previous 9 months * Patients with contraindication or difficulty to evaluate in the follow-up with OCT (renal failure, excessive tortuosity or lesions aorto-ostial)